Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/15/2025

Management of Autoimmune Hepatitis

Introduction to Treatment

  • The American Association for the Study of Liver Diseases recommends that all patients with active autoimmune hepatitis should receive combination therapy with prednisolone plus azathioprine as first-line treatment, which achieves remission in 80-90% of patients and significantly improves survival 1, 2

First-Line Treatment

  • The European Association for the Study of the Liver suggests starting prednisolone 30 mg/day combined with azathioprine 1-2 mg/kg/day, and tapering prednisolone over 4 weeks to a maintenance dose of 10 mg/day, then further reducing to 7.5 mg/day once aminotransferases normalize, and after 3 months taper to 5 mg/day 2, 3
  • The American College of Gastroenterology recommends maintaining azathioprine at 1-2 mg/kg/day as a steroid-sparing agent throughout treatment 2

Pre-Treatment Requirements

  • The American Gastroenterological Association advises checking thiopurine methyltransferase (TPMT) levels before starting azathioprine to exclude homozygote deficiency 1, 2
  • The European Association for the Study of the Liver suggests screening for hepatitis B (HBsAg, anti-HBc, anti-HBs) to identify patients requiring monitoring for reactivation 2

Treatment Monitoring and Goals

  • The American Association for the Study of Liver Diseases recommends that complete normalization of both ALT and IgG levels is the therapeutic endpoint, not just improvement 1, 2
  • The European Association for the Study of the Liver suggests assessing treatment response at 4-8 weeks after initiation, and monitoring serum aminotransferase levels monthly 3

Alternative First-Line Therapy

  • The American College of Gastroenterology recommends using budesonide 3 mg three times daily plus azathioprine (1-2 mg/kg/day) for non-cirrhotic patients at high risk for steroid side effects 6, 2

Management of Treatment Failure or Intolerance

  • The European Association for the Study of the Liver suggests increasing azathioprine to 2 mg/kg/day while continuing prednisolone (5-10 mg/day) for patients failing to achieve remission after 2 years on prednisolone plus azathioprine 6

Relapse Management

  • The American Association for the Study of Liver Diseases recommends that 50-90% of patients relapse within 12 months of stopping treatment following biochemical and histological remission, and that risk factors for relapse include raised serum ALT or AST at withdrawal, raised serum globulin/IgG, and liver biopsy with any inflammation or portal tract plasma cells 6, 3

Special Populations

  • The American College of Gastroenterology advises that azathioprine requires risk-benefit analysis but may be continued if disease control requires it during pregnancy 1, 2
  • The European Association for the Study of the Liver recommends using high-dose prednisone for up to 2 weeks, then gradual decrease to maintenance for children with AIH 1

Critical Pitfalls to Avoid

  • The American Gastroenterological Association warns that stopping treatment too early can result in 50-90% of patients relapsing within 12 months, and that persistent ALT elevation predicts poor outcomes including progressive fibrosis and liver-related death 2, 6

Lifelong Monitoring

  • The European Association for the Study of the Liver recommends that lifelong clinical and biochemical monitoring is mandatory, whether actively treated or not, and that patients should be under the supervision of a hepatologist or gastroenterologist with an interest in liver disease 6, 4, 5